Healthcare>Healthcare>Pharmaceuticals & Biotechnology>Pharmaceuticals
₹889.85
7.80 (0.88%)
High VOLATILITY
As on 10 Jul 2026
Price History
Market Cap
The total value of all a company's shares of stock. It's a quick way to gauge a company's size and value.
₹21.59K Cr
SMALL CAP
P/E Ratio
Price-to-Earnings ratio. It shows how much you pay for ₹1 of the company's earnings. A lower P/E might mean it's undervalued, but it varies by industry.
36.7
Industry
The specific business sector the company operates in. Useful for comparing with similar companies.
Pharmaceuticals
52-Week Range
The highest and lowest price at which the stock has traded in the last year (52 weeks). It helps show how volatile the stock is and where it is currently priced relative to its recent history.
52W Low₹432.6+105.7%
52W High₹901.8-1.3%
Current Price
₹889.85
Circuit Limits (20%)
The maximum allowed price movement (up or down) in a single trading day to prevent excessive volatility. If the stock hits these limits, trading may be temporarily halted.
Lower Circuit₹711.88
Upper Circuit₹1,067.82
Reference Price
₹889.85
Investment Checklist
Ascending Channel on 1W — target ₹916.55
Ascending Channel on 1D — target ₹916.55
Composite score 61.84 (STRONG_BUY) with 90.9% confidence
Trend: Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
RSI at 77.4 — overbought, pullback risk
Technical Analysis
Technical Analysis
Analysis from 2026-07-10
Confidence
91%
Trend
BULLISH
BULLISH
Price above all key MAs — strong uptrend | Bullish MA stack (20>50>200)
EMA20
820.04
EMA50
772.55
EMA200
649.88
Price Action
UPTREND
BULLISH
Higher Highs7
Higher Lows8
Lower Highs1
Lower Lows1
Support & Resistance Levels
Resistance (Above)
No recent resistance detected
Support (Below)
₹804.30
₹761.40
₹736.50
₹721.15
₹640.00
Volume Analysis
TrendINCREASING
Change+45.50%
Unusual VolumeNo
Stop Loss Levels
Fixed Risk
1% Risk₹880.95
3% Risk₹863.15
5% Risk₹845.36
7% Risk (Custom)
₹827.56Technical Levels
1x ATR (Volatility)₹863.82
2x ATR (Swing)₹837.79
3x ATR (Trend)₹811.76
Immediate Support₹804.30
Moving Averages
EMA 9 (Short-term)₹850.91
EMA 20 (Medium-term)₹820.04
EMA 50 (Trend)₹772.55
EMA 200 (Long-term)₹649.88
Financials
Financial Analysis
| Metric | Mar '25 | Jun '25 | Sep '25 | Dec '25 |
|---|---|---|---|---|
| Revenue | ₹1,196.8 Cr | ₹1,208.8 Cr | ₹1,294.7 Cr | ₹1,378 Cr |
| Net Profit | ₹152 Cr | ₹112.6 Cr | ₹130.6 Cr | ₹150.2 Cr |
| EPS | — | ₹4.64 | ₹5.38 | ₹6.19 |
| Operating Profit | ₹242.5 Cr | ₹237.1 Cr | ₹277.1 Cr | ₹304.5 Cr |
ROE
13.50%
ROCE
13.94%
Debt/Equity
0.39
Current Ratio
1.56
OPM
22.09%
NPM
10.90%
Peer Comparison
PharmaceuticalsPeer Comparison
Symbol | Name | Price | Change | P/E Ratio | Market Cap |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,935.50 | -0.17% | 40.2 | ₹4.64L Cr large Cap | |
| Divi's Laboratories Limited | ₹6,836.00 | +0.34% | 70.4 | ₹1.81L Cr large Cap | |
| Torrent Pharmaceuticals Limited | ₹4,901.50 | +0.07% | 77.5 | ₹1.66L Cr large Cap | |
| Cipla Limited | ₹1,439.40 | -0.13% | 30.1 | ₹1.16L Cr large Cap | |
| Zydus Lifesciences Limited | ₹1,150.80 | -0.71% | 23.0 | ₹1.16L Cr large Cap | |
| Lupin Limited | ₹2,496.30 | -0.28% | 21.4 | ₹1.14L Cr mid Cap | |
| Mankind Pharma Limited | ₹2,525.10 | -0.27% | 54.3 | ₹1.04L Cr mid Cap | |
| Dr. Reddy's Laboratories Limited | ₹1,244.30 | -1.99% | 25.6 | ₹1.04L Cr large Cap | |
| Aurobindo Pharma Limited | ₹1,564.70 | -1.43% | 26.1 | ₹90.88K Cr mid Cap | |
| Laurus Labs Limited | ₹1,537.80 | +2.02% | 91.5 | ₹83.02K Cr mid Cap | |
| Granules India Limited | ₹889.85 | +0.88% | 36.7 | ₹21.59K Cr small Cap |
Corporate Information
Large Deals
View AllBulk, Block and Short deals reported for this stock.
Loading Deals...
Corporate Actions
Recent actions
| Ex Date | Purpose | Type |
|---|---|---|
| 31 Jul 2025 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 30 Jul 2024 | Annual General Meeting/Dividend - Rs 1.50 Per Share | AGM |
| 03 Aug 2023 | Dividend - Rs 1.50 Per Share | DIVIDEND |
| 03 Aug 2023 | Annual General Meeting | AGM |
| 22 Aug 2022 | Buy Back | BUYBACK |
Announcements
Latest updates
Board Meetings
Upcoming and past meetings
Corporate Events
Upcoming results & meetings
| Date | Purpose | Type |
|---|---|---|
| 21 Jul 2026 | Financial Results | RESULTS |
Latest News
News for GRANULES
View AllNEWS
positive
Business Standard - Markets 5d ago
Granules India gains after securing sole first-to-file ANDA status for LUMRYZ generic
Granules India rose 2.14% to Rs 851 after the company said that it has secured sole first-to-file (FTF) status for its abbreviated new drug application (ANDA) for sodium oxybate extended-release for oral suspension.
GRANULESHealthcare
positive
CNBC TV18 - Markets 5d ago
Glenmark, Granules shares gain after USFDA developments; check details here
Glenmark Pharmaceuticals and Granules India announced key developments in the US market, including a product launch and a regulatory milestone that strengthen their generics portfolios.
GLENMARKGRANULESHealthcare
NEWS
positive
Business Standard - Markets 5d ago
Granules India secures FTF status for Sodium Oxybate ER for Oral Suspension ANDA
Granules India announced that it has secured Sole First-to-File (FTF) status for its Abbreviated New Drug Application (ANDA) for Sodium Oxybate Extended-Release for Oral Suspension, the generic equivalent of LUMRYZ extended-release oral suspension.
GRANULESHealthcare